Non-alcoholic fatty liver disease in patients with diabetes mellitus

References

• Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2025. Diabetes Res Clin Pract 2014;103(2):137-49
   PubMed Web of Science ®Google Scholar
• Muggeo M, Verlato G, Bonora E, et al. The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia 1995;38(3):318-25
   Google Scholar
• de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22(5):756-61
   PubMed Web of Science ®Google Scholar
• Balkau B, Eschwege E, Ducimetiere P, et al. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol 1991;44(6):465-74
   Google Scholar
• Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970;3:371-407
   PubMedGoogle Scholar
• Harman DJ, Kaye P, Harris R, et al. Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. Hepatology 2014. [Epub ahead of print]
   Google Scholar
• Wieland AC, Quallick M, Truesdale A, et al. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci 2013;58(10):2809-16
   PubMed Web of Science ®Google Scholar
• Kallmann JB, Arsalla A, Park V, et al. screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther 2009;29(9):1019-24
   Google Scholar
• Bergqvist CJ, Skoien R, Horsfall L, et al. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J 2013;43(3):247-53
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Hazlehurst JM, Parker R, et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care: a multi-disciplinary team approach to diagnosis and management. QJM 2014;107(1):33-41
   Google Scholar
• Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60(12):1721-7
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30(5):1212-18
   PubMed Web of Science ®Google Scholar
• Leung CM, Lai LS, Wong WH, et al. Non-alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong. J Gastroenterol Hepatol 2009;24(11):1786-90
   Google Scholar
• Wieland AC, Mettler P, McDermott MT, et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol 2014. [Epub ahead of print]
   Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40(6):1387-95
   PubMed Web of Science ®Google Scholar
• Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30(3):734-43
   PubMed Web of Science ®Google Scholar
• Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85(10):1349-55
   Google Scholar
• Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a large middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140(1):124-31
   PubMed Web of Science ®Google Scholar
• Scaglioni F, Ciccia S, Marino M, et al. ASH and NASH. Dig Dis 2011;29(2):202-10
   Google Scholar
• Maheshwari A, Thuluvath PJ. Cryptognic cirrhosis and NAFLD: are they related? Am J Gastroenterol 2006;101(3):664-8
   Google Scholar
• Shetty A, Wilson S, Kuo P, et al. Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation 2000;69(11):2451-4
   PubMedGoogle Scholar
• Marchesini G, Bianchi GP, Forlani G, et al. Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. Dig Dis Sci 1987;32(10):1118-24
   Google Scholar
• del Vecchio Blanco C, Gentile S, Marmo R, et al. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990;8(1):29-36
   Google Scholar
• Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55(7):434-8
   PubMed Web of Science ®Google Scholar
• Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11(1):74-80
   PubMed Web of Science ®Google Scholar
• Adami HO, Chow WH, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes. J Natl Cancer Inst 1996;88(20):1472-7
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126(2):460-8
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012;107(2):253-61
   PubMed Web of Science ®Google Scholar
• Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010;26(9):2183-91
   PubMed Web of Science ®Google Scholar
• Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51(6):1972-8
   PubMed Web of Science ®Google Scholar
• Fuchs M, Sanyal AJ. Non-alcoholic fatty liver disease: a pathophysiological perspective. In: Arias IM, Alter HJ, Boyer JL, et al. editors. The liver. Biology and Pathobiology. 5th edition. Wiley & Sons; NJ, USA: 2010. p. 719-41
   Google Scholar
• Payne AN, Chassard C, Lacroix C. Gut microbial adaptation to dietary consumption of fructose, artificial sweeteners and sugar alcohols: implications for host-microbe interactions contributing to obesity. Obes Rev 2012;13(9):799-809
   PubMed Web of Science ®Google Scholar
• Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009;137(5):1716-24
   PubMed Web of Science ®Google Scholar
• Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1877-87
   PubMed Web of Science ®Google Scholar
• Wigg AJ, Roberts-Thompson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48(2):206-11
   PubMed Web of Science ®Google Scholar
• Wagnerberger S, Spruss A, Kanuri G, et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012;107(12):1727-38
   Google Scholar
• Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48(6):983-92
   PubMed Web of Science ®Google Scholar
• Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50(4):1094-104
   PubMed Web of Science ®Google Scholar
• Devkota S, Wang Y, Musch MW, et al. Dietary-fat induced taurocholic acid promotes pathobiont expansion and colitis in IL10-/- mice. Nature 2012;487(7405):104-8
   PubMed Web of Science ®Google Scholar
• Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by nuclear bile acid receptor. Proc Natl Acad Sci USA 2006;103(10):3920-5
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57(2):601-9
   PubMed Web of Science ®Google Scholar
• Volynets V, Kuper MA, Strahl S, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012;57(7):1932-41
   PubMed Web of Science ®Google Scholar
• Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17(10):1374-80
   PubMed Web of Science ®Google Scholar
• Poniachik L, Csendes A, Diez JC, et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 2006;33(5):252-7
   Google Scholar
• Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138(8):1452-5
   Google Scholar
• Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol 2011;45(2):149-52
   Google Scholar
• Munukka E, Pekkala S, Wiklund P, et al. Gut-adipose tissue axis in hepatic fat accumulation in humans. J Hepatol 2014;61(1):132-8
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444(7122):1027-31
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444(7122):1022-3
   PubMed Web of Science ®Google Scholar
• Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101(44):15718-23
   PubMed Web of Science ®Google Scholar
• Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007;104(3):979-84
   PubMed Web of Science ®Google Scholar
• Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012;28(2):159-65
   PubMed Web of Science ®Google Scholar
• Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006;103(33):12511-16
   PubMed Web of Science ®Google Scholar
• Guerrerio AL, Colvin RM, Schwartz AK, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 2012;95(4):892-900
   PubMed Web of Science ®Google Scholar
• Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134(2):424-31
   Google Scholar
• Hwang JH Stein DT, Barzilai N, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 2007;293(6):E1663-9
   Google Scholar
• Donnelly KL, Smith CL, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115(5):1343-51
   PubMed Web of Science ®Google Scholar
• Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011;60(10):1394-402
   PubMed Web of Science ®Google Scholar
• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332(6037):1519-23
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Linfoot P, Dare D, et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003;77(1):43-50
   Google Scholar
• Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146(3):726-35
   PubMed Web of Science ®Google Scholar
• Fuchs M, Sanyal AJ. Lipotoxicity in NASH. J Hepatol 2012;56(1):291-3
   PubMed Web of Science ®Google Scholar
• Zein CO, Lopez R, Fu X, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012;56(4):1291-9
   PubMed Web of Science ®Google Scholar
• Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50(6):1827-3
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Lopez R, Tamimi TA, et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010;51(10):3046-54
   PubMed Web of Science ®Google Scholar
• Santoro N, Caprio S, Giannini C, et al. Oxidized fatty acids: a potential pathogenic link between fatty liver and type 2 diabetes mellitus in obese adolescents? Antioxid Redox Signal 2014;20(2):383-9
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114(4):842-5
   PubMed Web of Science ®Google Scholar
• Cheung O, Puri P. Eicken C, et al. nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008;48(6):1810-20
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52
   PubMed Web of Science ®Google Scholar
• Pacana T, Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis 2012;16(3):599-613
   Google Scholar
• Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33(10):1190-200
   Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363(14):1341-50
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865-73
   PubMed Web of Science ®Google Scholar
• Söderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year-follow-up. Hepatology 2010;51(2):595-602
   PubMed Web of Science ®Google Scholar
• Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7(2):234-8
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43(4):682-9
   PubMed Web of Science ®Google Scholar
• Browning JD, Kumar KS, Saboorian MH, et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99(2):292-8
   Google Scholar
• Williams CD, Stengel J, Asike MI, et al. Prevalence of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140(1):124-31
   PubMed Web of Science ®Google Scholar
• Mohanty SR, Troy TN, Huo D, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009;50(4):797-804
   PubMed Web of Science ®Google Scholar
• Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108(1):9-13
   Google Scholar
• Willner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96(10):2957-61
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136(5):1585-92
   PubMed Web of Science ®Google Scholar
• Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10(11):645-55
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40(12):1461-5
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53(6):1883-94
   PubMed Web of Science ®Google Scholar
• Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61(1):75-8
   PubMed Web of Science ®Google Scholar
• Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012;15(5):691-702
   PubMed Web of Science ®Google Scholar
• Naik A, Kosir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics 2013;102(2):84-95
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Bo S, et al. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62(4):1109-20
   Google Scholar
• Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447(7143):433-40
   PubMed Web of Science ®Google Scholar
• Braun R, Buetow K. Pathways of distinction analysis: a new technique for multi-SNP analysis of GWAS data. PLoS Genet 2011;7(6):e1001324
   Google Scholar
• Zain SM, Mohamed R, Cooper DN, et al. Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease. PLoS One 2014;9(4):e95604
   Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005-23
   PubMed Web of Science ®Google Scholar
• Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54(3):1082-90
   PubMed Web of Science ®Google Scholar
• Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51(3):433-45
   PubMed Web of Science ®Google Scholar
• Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicenter retrospective study on 68,276 biopsies. J Hepatol 1986;2(2):165-73
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128(7):1898-906
   PubMed Web of Science ®Google Scholar
• Mofrad P, Contos MJ, Haque M, et al. Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37(6):1286-92
   PubMed Web of Science ®Google Scholar
• Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-7
   PubMed Web of Science ®Google Scholar
• McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59(9):1265-9
   PubMed Web of Science ®Google Scholar
• McPherson S, Henderson E, Burt AD, et al. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60(5):1055-62
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104-12
   PubMed Web of Science ®Google Scholar
• Morling JR, Fallowfield JA, Guha IN, et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J Hepatol 2014;60(2):384-91
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107(5):450-5
   PubMed Web of Science ®Google Scholar
• Cobbold JFL, Patel D, Taylor-Robinson SD. Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques. J Gastroenterol Hepatol 2012;27(8):1281-92
   Google Scholar
• Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014;146(1):46-62
   Google Scholar
• Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40(Suppl 1):S39-43
   Google Scholar
• Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013;36(11):3821-42
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008;48(6):1791-8
   Google Scholar
• Boule NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001;286(10):1218-27
   PubMed Web of Science ®Google Scholar
• Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009;44(12):1203-8
   Google Scholar
• Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50(4):1105-12
   PubMed Web of Science ®Google Scholar
• Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106(3):460-8
   PubMed Web of Science ®Google Scholar
• St. George A, Bauman A, Johnston A, et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50(1):68-76
   PubMed Web of Science ®Google Scholar
• Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012;56(1):255-66
   PubMed Web of Science ®Google Scholar
• Centis E, Marzocchi R, Di Domizio S, et al. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis 2010;28(1):267-73
   Google Scholar
• Stewart KE, Haller DL, Sargeant C, et al. Readiness for behavior change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int 2014. [Epub ahead of print]
   Google Scholar
• Conlon BA, Beasley JM, Aebersold K, et al. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients 2013;5(10):4093-114
   PubMedGoogle Scholar
• McCarthy EM, Rinella ME. The role of diet and nutrition composition in nonalcoholic fatty liver disease. J Acad Nutr Diet 2012;112(3):401-9
   Google Scholar
• Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48(6):993-9
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Nitzan-kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007;47(5):711-17
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37(4):909-16
   PubMed Web of Science ®Google Scholar
• Lindqvist A, Baelemans A, Erlanson-Albertsson C. Effects of sucrose, glucose and fructose on peripheral and central appetite signals. Regul Pept 2008;150(1-3):26-32
   PubMedGoogle Scholar
• Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009;119(5):1322-34
   PubMed Web of Science ®Google Scholar
• Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003;29(5):478-85
   Google Scholar
• Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005;63(5):133-57
   PubMed Web of Science ®Google Scholar
• Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006;147(2):943-51
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Araya J, et al. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006;12(12):555-8
   PubMed Web of Science ®Google Scholar
• Julius U. Fat modification in the diabetes diet. Exp Clin Endocrinol Diabetes 2003;111(2):60-5
   Google Scholar
• Rodriguez-Villar C, Perez-Heras A, Mercade I, et al. Comparison of a high-carbohydrate and a high-monounsaturated fat, olive oil-rich diet on the susceptibility of LDL to oxidative modification in subjects with type 2 diabetes mellitus. Diabet Med 2004;21(2):142-9
   Google Scholar
• Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem 2006;17(1):1-13
   PubMed Web of Science ®Google Scholar
• Erhardt A, Stahl W, Sies H, et al. Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH). Eur J Med Res 2011;16(2):76-8
   Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, et al. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38(12):2293-301
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675-85
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2(12):1107-15
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013;38(2):134-43
   PubMed Web of Science ®Google Scholar
• Cheng J, Joyce A, Yates K, et al. Metabolomics profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH). PLoS One 2012;7(9):e44106
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trials (SELECT). JAMA 2011;306(14):1549-56
   PubMed Web of Science ®Google Scholar
• Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomized controlled trials. BMJ 2010;341:c5702
   PubMed Web of Science ®Google Scholar
• Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142(1):37-46
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333(9):550-4
   PubMed Web of Science ®Google Scholar
• Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther 2014;31(1):30-43
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30(5):750-8
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Bao JQ, Day JS, et al. Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. Drug Metab Dispos 2013;41(11):1967-71
   PubMedGoogle Scholar
• Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50(2):81-98
   PubMed Web of Science ®Google Scholar
• Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010;33(9):727-40
   Google Scholar
• Bourron O, Daval M, Hajduch E, et al. Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase. Diabetologia 2010;53(4):768-78
   PubMed Web of Science ®Google Scholar
• Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 2010;95(5):2163-71
   PubMedGoogle Scholar
• DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364(12):1104-15
   PubMed Web of Science ®Google Scholar
• van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4(4):249-63
   Google Scholar
• Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52(1):79-104
   PubMed Web of Science ®Google Scholar
• Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46(2):424-9
   PubMed Web of Science ®Google Scholar
• Yau H, Rivera K, Lomonaco R, et al. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 2013;13(3):329-41
   Google Scholar
• Cohen DE, Anania FA, Chalasani N, et al. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77C-81C
   Google Scholar
• Sattar N, Taskinen MR. Statins are diabetogenic – myth or reality. Atheroscler Suppl 2012;13(1):1-10
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376(9756):1916-22
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89(1):147-91
   PubMed Web of Science ®Google Scholar
• Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012;17(17-18):988-97
   PubMed Web of Science ®Google Scholar
• Fuchs M. Non-alcoholic fatty liver disease: the bile acid-activated farnesoid X receptor as emerging treatment target. J Lipids 2012;2012:934396
   Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145(3):574-82
   PubMed Web of Science ®Google Scholar
• Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54(8):2460-70
   PubMed Web of Science ®Google Scholar
• Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodents of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013;58(6):1941-52
   PubMed Web of Science ®Google Scholar
• Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34(9):2008-14
   PubMed Web of Science ®Google Scholar
• Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology 1996;23(6):1464-7
   PubMed Web of Science ®Google Scholar